Suppr超能文献

Akt/蛋白激酶b和糖原合酶激酶-3β信号通路通过NFAT1转录因子调节细胞迁移。

Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor.

作者信息

Yoeli-Lerner Merav, Chin Y Rebecca, Hansen Christopher K, Toker Alex

机构信息

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

出版信息

Mol Cancer Res. 2009 Mar;7(3):425-32. doi: 10.1158/1541-7786.MCR-08-0342. Epub 2009 Mar 3.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway regulates a multitude of cellular processes. Deregulation of PI3K signaling is often observed in human cancers. A major effector of PI3K is Akt/protein kinase B (PKB). Recent studies have pointed to distinct roles of Akt/PKB isoforms in cancer cell signaling. Studies have shown that Akt1 (PKBalpha) can attenuate breast cancer cell motility, whereas Akt2 (PKBbeta) enhances this phenotype. Here, we have evaluated the mechanism by which Akt1 blocks the migration of breast cancer cells through the transcription factor NFAT. A major effector of Akt/PKB is glycogen synthase kinase-3beta (GSK-3beta), also a NFAT kinase. Inhibition of GSK-3beta using short hairpin RNA or a selective inhibitor potently blocks breast cancer cell migration concomitant with a reduction in NFAT activity. GSK-3beta-mediated inhibition of NFAT activity is due to proteasomal degradation. Experiments using GSK-3beta mutants, which are unresponsive to Akt/PKB, reveal that inhibition of cell migration by Akt/PKB is mediated by GSK-3beta. These effects are recapitulated at the levels of NFAT degradation by the proteasome. Our studies show that activation of Akt/PKB leads to inactivation of the effector GSK-3beta and the outcome of this signaling event is degradation of NFAT by the proteasome and subsequent inhibition of cell migration.

摘要

磷酸肌醇3激酶(PI3K)信号通路调控众多细胞过程。PI3K信号失调在人类癌症中经常可见。PI3K的一个主要效应分子是Akt/蛋白激酶B(PKB)。最近的研究指出Akt/PKB亚型在癌细胞信号传导中的不同作用。研究表明,Akt1(PKBα)可减弱乳腺癌细胞的迁移能力,而Akt2(PKBβ)则增强这种表型。在此,我们评估了Akt1通过转录因子NFAT阻断乳腺癌细胞迁移的机制。Akt/PKB的一个主要效应分子是糖原合酶激酶-3β(GSK-3β),它也是一种NFAT激酶。使用短发夹RNA或选择性抑制剂抑制GSK-3β可有效阻断乳腺癌细胞迁移,同时NFAT活性降低。GSK-3β介导的NFAT活性抑制是由于蛋白酶体降解。使用对Akt/PKB无反应的GSK-3β突变体进行的实验表明,Akt/PKB对细胞迁移的抑制是由GSK-3β介导的。这些效应在蛋白酶体对NFAT的降解水平上得到了重现。我们的研究表明,Akt/PKB的激活导致效应分子GSK-3β失活,这一信号事件的结果是蛋白酶体降解NFAT并随后抑制细胞迁移。

相似文献

引用本文的文献

8
Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.基质 SNAI2 对于 ERBB2 乳腺癌的进展是必需的。
Cancer Res. 2020 Dec 1;80(23):5216-5230. doi: 10.1158/0008-5472.CAN-20-0278. Epub 2020 Oct 6.

本文引用的文献

1
A new mutational AKTivation in the PI3K pathway.PI3K 通路中的一种新的突变激活
Cancer Cell. 2007 Aug;12(2):104-7. doi: 10.1016/j.ccr.2007.07.014.
2
AKT/PKB signaling: navigating downstream.AKT/蛋白激酶B信号传导:下游通路解析
Cell. 2007 Jun 29;129(7):1261-74. doi: 10.1016/j.cell.2007.06.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验